Last reviewed · How we verify
NCT06350305
Screening for High-risk Chronic Obstructive Pulmonary Disease
trial testing questionnaire survey in High-risk COPD in 3,600 participants. Not yet recruiting.
30 April 2027
Quick facts
| Lead sponsor | Henan University of Traditional Chinese Medicine |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 3,600 |
| Start date | 1 May 2024 |
| Primary completion | 30 April 2027 |
| Estimated completion | 31 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- questionnaire survey
Conditions studied
- High-risk COPD — all drugs for High-risk COPD →
Sponsor
Henan University of Traditional Chinese Medicine
Who can join
Adults 18 to 80, any sex, with High-risk COPD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter cross-sectional study design aimed at screening risk factors for the combination of disease and syndrome in high-risk individuals with chronic obstructive pulmonary disease (COPD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06350305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of questionnaire survey
Trials testing the same drug.
- NCT07335744 — Construction of a Multidimensional Risk Prediction Model for Severe Early Childhood Caries · not yet recruiting
- NCT06006234 — Analysis of Anxiety and Depression Among Elderly People · unknown
- NCT06573450 — Exhaled Breath Condensate Biomarkers in CARAS · recruiting
- NCT05461924 — The Long Term Outcomes After Pull-through of Long Segment Hirschsprung Disease · unknown
- NCT05443217 — Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments · unknown
Other Henan University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
- NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
- NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
- NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
- NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06350305 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06350305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing